Skip to content

Study · Observational study · n = 11 · 1999

2 results

High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.

Kol S, Lightman A, Hillensjo T, Devroey P, Fauser B, Tarlatzis B, Mannaerts B, Itskovitz-Eldor J

Human reproduction (Oxford, England)1 Sept 1999Cited by 60 (Europe PMC)

PMID10469687 (opens in a new tab)DOI10.1093/humrep/14.9.2242 (opens in a new tab)PepBankPUB-10469687
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    Among the 11 ongoing pregnancies after frozen embryo transfer, six patients had received high-dose ganirelix during the original IVF cycles.

    In plain wordsAmong 11 ongoing pregnancies after frozen embryo transfer, six patients had received high-dose ganirelix during their IVF cycles.

    Peptide
    Ganirelix
    Outcome
    Not applicableOngoing pregnancies after high-dose exposure
    Study

    n = 11

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.0 or 2.0 mg once dailyAs given in this study (human).

    Measurements

    Patients treated with high-dose ganirelix (1.0 or 2.0 mg)
    6 patients
    of 11 ongoing pregnancies

    Source sentences

    Summary
    Six of these 11 patients had been treated with a high dose of ganirelix (1.0 or 2.0 mg) during the IVF cycles in which the embryos were obtained.
    3 context sentences
    Summary · context
    This follow-up study reports on the pregnancy rate after replacement of cryopreserved embryos obtained in stimulation cycles of the above-mentioned trial.
    Summary · context
    Ganirelix (0.0625, 0.125, 0.25, 0.5, 1.0 or 2.0 mg) was administered once daily from stimulation day 6 onwards, up to and including the day of human chorionic gonadotrophin.
    Summary · context
    Excess embryos were frozen, and subsequently used in either natural or programmed cycles.
  2. 02HumanObservational studyEfficacy outcome

    After ganirelix stimulation, frozen embryo transfers produced 11 ongoing pregnancies at 12-16 weeks from 46 cycles, or 23.9% per transfer.

    In plain wordsAfter ganirelix stimulation, frozen embryo transfers produced 11 ongoing pregnancies from 46 cycles, or 23.9% per transfer.

    Peptide
    Ganirelix
    Outcome
    Not applicableOngoing pregnancies after frozen embryo transfer
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.0625-2.0 mg once dailyAs given in this study (human).

    Measurements

    Ongoing pregnancies after frozen embryo transfer
    11 pregnancies
    12-16 weeks after embryo transfer; 46 cycles with first-frozen embryos
    Ongoing pregnancy rate per transfer
    23.9%
    46 cycles with first-frozen embryos

    Source sentences

    Summary
    Until June 1998, 11 ongoing pregnancies (12-16 weeks after embryo transfer) were achieved from 46 cycles in which embryos had been first frozen (23.9% per transfer).
    3 context sentences
    Summary · context
    This follow-up study reports on the pregnancy rate after replacement of cryopreserved embryos obtained in stimulation cycles of the above-mentioned trial.
    Summary · context
    Ganirelix (0.0625, 0.125, 0.25, 0.5, 1.0 or 2.0 mg) was administered once daily from stimulation day 6 onwards, up to and including the day of human chorionic gonadotrophin.
    Summary · context
    Excess embryos were frozen, and subsequently used in either natural or programmed cycles.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.